Cancer vaccine (AlloStim) - Immunovative Therapies

Drug Profile

Cancer vaccine (AlloStim) - Immunovative Therapies

Alternative Names: AlloStim; AlloStim-7; AlloStim-8; AlloStim-9; Bioengineered allogeneic immune cells (AlloStim); InSituStim; InSituVax; Intentionally mis-matched, allogeneic Th1 memory Cells (AlloStim) conjugated With CD3/CD28-coated microbeads; Mis-matched immune cell therapy (AlloStim) - Immunovative Therapies; Personalized anti-tumour vaccine - Immunovative Therapies

Latest Information Update: 25 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunovative Therapies
  • Class Cancer vaccines; Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 07 Nov 2016 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (Intradermal)
  • 07 Nov 2016 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (Intratumoural)
  • 07 Nov 2016 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top